Morphic Therapeutic Revenue and Competitors

Boston, MA USA

Location

$134.5M

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Morphic Therapeutic's estimated annual revenue is currently $26.3M per year.(i)
  • Morphic Therapeutic received $80.0M in venture funding in September 2018.
  • Morphic Therapeutic's estimated revenue per employee is $201,000
  • Morphic Therapeutic's total funding is $134.5M.

Employee Data

  • Morphic Therapeutic has 131 Employees.(i)
  • Morphic Therapeutic grew their employee count by 12% last year.

Morphic Therapeutic's People

NameTitleEmail/Phone
1
Sr. VP Finance & CAOReveal Email/Phone
2
CEOReveal Email/Phone
3
SVP Regulatory Affairs & QualityReveal Email/Phone
4
SVP, Head Biology and Translational SciencesReveal Email/Phone
5
VP DMPK & Clin PharmReveal Email/Phone
6
SVP, Technical OperationsReveal Email/Phone
7
VP, Head Chemical SciencesReveal Email/Phone
8
General Counsel, Corporate Secretary and Chief Compliance OfficerReveal Email/Phone
9
SVP Corporate Business DevelopmentReveal Email/Phone
10
VP, Clinical OperationsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$413.3M3240%$634MN/A
#2
$47.8M2380%N/AN/A
#3
$2.4M12-52%N/AN/A
#4
$25.7M12839%N/AN/A
#5
$12.9M64129%N/AN/A
#6
$23.9M1198%$113MN/A
#7
$0.3M30%N/AN/A
#8
$10.3M51-14%N/AN/A
#9
$1.8M367-4%$538MN/A
#10
$50M2493%N/AN/A
Add Company

What Is Morphic Therapeutic?

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$134.5M

Total Funding

131

Number of Employees

$26.3M

Revenue (est)

12%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Morphic Therapeutic News

2022-04-19 - Global Integrin Alpha V Market Insights Report 2022, Trends ...

Biogen Inc, BioMAS Ltd, Factor Therapeutics Ltd, MedImmune LLC, Merck & Co Inc, Merck KGaA, Morphic Therapeutic Inc, SciFluor Life Sciences LLC, Vascular...

2022-03-30 - Morphic Therapeutic Expands Leadership with Key Appointments in ...

Morphic Therapeutic is a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic...

2022-03-22 - Clinical Catch-Up: Moderna COVID-19 Vaccine for Kids and Much ...

NeuroSense Therapeutics announced the FDA had cleared its IND for PrimeC, ... Morphic Therapeutic initiated the EMERALD1 Phase IIa trial of...

2019-09-07 - Cartoons’ similarity creates headache for biotech CEO

Praveen Tipirneni, CEO of Waltham-based Morphic Therapeutic, is taking flack for a cartoon he drew about the biotech industry that bears a ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.5M132-14%N/A
#2
$27.9M1330%N/A
#3
$41.9M1415%N/A
#4
$17.5M14734%$333M
#5
$18.9M14723%$137.5M

Morphic Therapeutic Funding

DateAmountRoundLead InvestorsReference
2016-07-01$51.5MASR OneArticle
2018-09-26$80.0MBOmega FundsArticle